Fragmentomics of cell-free DNA from targeted panels in genitourinary malignancies.

Media type: E-Article

Title: Fragmentomics of cell-free DNA from targeted panels in genitourinary malignancies

Contributor: Taylor, Amy K; Helzer, Kyle; Sharifi, Marina Nasrin; Sperger, Jamie M; Shi, Yue; Annala, Matti; Reese, Shannon; Kaufmann, Katherine; Schehr, Jennifer L.; Sethakorn, Nan; Kosoff, David; Kyriakopoulos, Christos; Armstrong, Andrew J.; McKay, Rana R.; Feng, Felix Y; Wisinski, Kari Braun; Emamekhoo, Hamid; Wyatt, Alexander William; Lang, Joshua Michael; Zhao, Shuang

imprint: American Society of Clinical Oncology (ASCO), 2024

Language: English

DOI: 10.1200/jco.2024.42.4_suppl.199

ISSN: 1527-7755; 0732-183X

Keywords: Cancer Research ; Oncology

Origination:

Footnote:

Description: 199 Background: The detection of genomic alterations in cancer is critical for identifying clinically actionable alterations for treatment decisions. Tumor samples historically have been required, but obtaining tissue for molecular profiling is not always feasible, especially in the metastatic setting. The isolation and analysis of cell-free DNA (cfDNA) including circulating tumor DNA (ctDNA) via blood-based “liquid” biopsies offers non-invasive sampling of the tumor. Recently, fragmentation patterns of cfDNA (i.e. “fragmentomics”) have emerged as a method for inferring epigenomic and transcriptomic information. However, these analyses use whole-genome sequencing, which lacks the necessary depth to cost-effectively assess genomic alterations, limiting the application of these techniques clinically. Methods: We developed a novel cfDNA fragmentomics machine learning approach for standard targeted cancer gene panels in order to identify genitourinary (GU) and non-GU cancers from two independent metastatic cancer cohorts: a published cohort from GRAIL (prostate cancer, non-GU cancers, normal samples, N=198) and an expanded institutional cohort from the University of Wisconsin (prostate adenocarcinoma, neuroendocrine prostate cancer (NEPC), renal cell carcinoma (RCC), bladder cancer, non-GU cancers, normal samples, n = 431). Results: In the GRAIL cohort, 10-fold cross-validation AUCs were 0.987 for identifying prostate cancer, 1.00 for normal samples, and ranged from 0.922-0.958 for the non-GU cancers. In the UW cohort, 10-fold cross-validation AUCs were 0.950 for bladder cancer, 0.982 for prostate cancer, 0.993 for NEPC, 0.925 for RCC, and 0.980 for normal samples, and ranged from 0.874-0.954 for non-GU cancers. Our assay can sensitively detect and accurately distinguish GU and non-GU malignancies despite a median ctDNA fraction of only 0.076 in the GRAIL cohort, and a median ctDNA fraction of only 0.022 in the UW cohort. Conclusions: Our enhanced machine learning approach for examining fragmentomics in standard cancer gene cfDNA panels unlocks the potential for these established assays to be utilized to answer critical clinical questions beyond somatic variant identification. The excellent performance of our innovative approach even in samples with low ctDNA fractions suggest potential applications such as multi-cancer early detection and minimal residual disease monitoring. This framework could dramatically expand the potential of already existing clinically used assays and minimizes barriers for continued biomarker development.

Search in field:

Recently searched for: